NasdaqGM:ATAIPharmaceuticals
AtaiBeckley CFO Change Puts Funding And Dilution In Sharper Focus
AtaiBeckley (NasdaqGM:ATAI) has appointed Michael Faerm as Chief Financial Officer.
Faerm will oversee the company’s financial strategy and operations.
The company highlighted his prior experience across multiple biopharmaceutical companies.
For investors, this move sits at the intersection of leadership and late stage drug development, since AtaiBeckley is advancing several programs through the clinical funnel. In biopharma, the CFO role often covers areas ranging from clinical funding...